

## ASX ANNOUNCEMENT MARKET RELEASE 5 May 2025

# SECONDARY TRADING NOTICE – NOTIFICATION PURSUANT TO PARAGRAPH 708A(5)(E) OF THE CORPORATIONS ACT 2001

Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company focused on commercialising its patented AI platform that detects, diagnoses and helps address coronary artery disease, provides this notice in accordance with section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) in relation to an issue today of 100,000 fully paid ordinary shares by Artrya on the exercise of vested employee incentive restricted stock units.

- 1. The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2. As at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act.
- 3. As at the date of this notice, there is no excluded information (in accordance with the requirements of subsections 708A(7) and (8) of the Corporations Act.

#### **Artrya Limited**

Kevin Hart Company Secretary

This announcement was approved for release by the Company Secretary.

#### For further information please contact:

Investor Enquiries:
Danny Younis
+61 420 293 042
danny.younis@automicgroup.com.au

Media Relations: Rama Razy

+61 498 440 142

rama.razy@automicgroup.com.au

### **About Artrya**

Artrya Limited (ASX: AYA) is an Australian medical technology company developing Al-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets

For more information, see www.artrya.com